Supplementary Table 1: Primers used in this study:

Rv1222 fw(Ndel)	GGATCCATATGGCCGACCCCGGAAGCGT		
Rv1222 rv(HindIII)	AAGCTTCTAGCGACGCACCCGCGATTG		
Rv1222 rv(EcoRI)	ATGAATTCATGGCCGACCCCGGAAGCG		
Rv1222 C70/73A fw	CCTTTCGCTGGCTGCCCAAGCCGCGGCCGAAG		
Rv1222 C70/73A rv	CTTCGGCCGCGGCTTGGGCAGCCAGCGAAAGG		
Rv1222 C109G fw	CCGAGATCCCGCGTGGTCCACCTGAAGG		
Rv1222 C109G rv	CCTTCAGGTGGACCACGCGGGATCTCGG		
Rv1222 A23C fw	CCCGGCGCAGTTCTGCTCCCAGAGTGAC		
Rv1222 A23C rv	GTCACTCTGGGAGCAGAACTGCGCCGGG		
Rv1222 G133C fw	GGGCTGCGGCATGCTTCGGCGAC		
Rv1222 G133C rv	GTCGCCGAAGCATGCCGCAGCCC		
Rv1222∆C fw	GCTTCGCTGACGGCTGATGGCGGGAATC		
Rv1222∆C rv	GATTCCCGCCATCAGCCGTCAGCGAAGC		
lacCONS fw	ATGGTACCTAGGCACCCCAGGCTTG		
lacCONS rv	ATGGATCCTGTGTGAAATTGTTATCCGC		
DNA pol cy5 rv	GAAGGTGAAAGGCCTTTCG		
<i>abrB</i> fw	AAGAATTCGTTTCCAAGACATTACTGACTATAAG		
<i>abrB</i> rv	TTCTCCTCCCAAGAGATACTTATTTG		
<i>Bpr</i> fw	CGTCTGTTGGCCGGCG		
<i>Bpr</i> rv	CCCTTGTGGGTGCATCGG		
<i>sinP3</i> fw	CAGCCAGAAGTCATACCG		
<i>sinP3</i> rv	GCCAAGCTTGCATGCCT		
<i>rrnA</i> fw	TCTGGTACCTCGTGGAGAACCTGGTGAGTC		
<i>rrnA</i> rv	TCTGGATCCTACGCCGCCAGCGTTCGT		
sigE fw(EcoRV)	ATGATATCATGGAACTCCTCGGCGGACC		
SigE rv(Xhol)	TACTCGAGTCAGCGAACTGGGTTGACGTG		
T7 fw	CCCGCGAAATTAATACGACTCACTATAGGGG		
T7 rv	GCTAGTTATTGCTCAGCGGTGGC		
<i>T7A1</i> fw	CGGAATTCGGATCCAGATCCCG		
<i>T7A1</i> rv	CCTTTTTCACAGGTTTATAACCC		

Supplementary Table 2: Templates used in this study:

Tailed- template	Used in <i>in vitro</i> transcription assay with Mtb RNAPcore	CCTTGAGTTTCAGGCCGAAACAGCAATTTGGGGTACTGTCACGTTCGGCTAGCCCTCCAGCCCCCCCC	
Bpr	Used in EMSA and <i>in vitro</i> transcription assay with RNAP- σ ^E holo	TAGCCGTCTGTTGGCCGGCGTTCCGGGTTGTCGGCCACTGGCCACACTTCTCAGGACTTTCTCAGGTCTT CGGCAGATTCCTGCACGTCACAGGGCGTCAGATCACTGCTGGGTGGG	
lacCONS15	Used in <i>in vitro</i> transcription assay with Ec RNAP- σ^{70} holo.	CACCCCAGGCTTGACACTTTATGCTTCGGCTCGTATAATGTGTGGA A TTGTGAGGAGAGGGG GATAACAA TT TCACACAGG	
lacCONS	Used in <i>in vivo</i> reporter assay	TAGGCACCCCAGGCTTGACACTTTATGCTTCGGCTCGTATAATGTGTGGGA A TTGTGAGCGGATAACAATTT CACACAGG	
sinP3	Used in <i>in vitro</i> transcription assay with Mtb RNAP- σ^{A} holo (time kinetics)	CAGCCAGAAGTCATACCGTAAATCCTTTCTGAATGTGCTATAATATCACA A TTGCTCGATGAGAAACATGAA ACCGAATACGGATCCTCTAGAGTCGACCTGCAGGCATGCAAGCTTGGC	
rrnA	Used in <i>in vitro</i> transcription assay with Mtb RNAP- σ ^A holo	TCGTGGAGAACCTGGTGAGTCTCGGTGCCGAGATCGAACGGGTATGCTGTTAG G CGACGGTCACCTATG GATATCTATGGATGACCGAACCTGGTCTTGACTCCATTGCCGGATTTGTATTAGACTGGCAGGGTCGCCC CGAAGCGGGCGGAAACAAGCAAGCGTGTTGTTTGAGAACTCAATAGTGTGTTTGGTGGTTTCACATTTTT GTTGTTATTTTTGGCCATGCTCTTGATGCCCCGTTGTCGGGGGGCGTGGCCGTTTGTTT	
abrB	Used in <i>in vitro</i> transcription assay with Bs RNAP.	AAGAATTCGTTTCCAAGACATTACTGACTATAAGAACTAATTCTTACAATCAAT	
TEMPLATE for <i>in vitro</i> replication	Used in <i>in vitro</i> replication assay with Klenow fragment	CGAAGTTGACTTTTCACTGGTTTTTTCACTTAACAAAACAGAAGGGAAAACGAAAGGCCTTTCA	
Promoter- less DNA	Used in anisotropy assay	GTGAGTATCTCGCAGTCCGACGCGTCGTTGGCCGCCGTCCCCGCCGTGGATCAGTTCGATCCGTCGTC AGGTGCATCAGGTGGCTACGACACCCCGCTGGGCATCACCAATCCGCCCATCGACGAGTTGCTGGACC GCGTCTCGAGCAAATACGCCCTCGTGATCTATGCGGCAAAGCGTGCCCGGCAGATCAACGACTACTACA ACCAGCTTGGCGAGGGCATCCTCGAATATGTCGGTCCGCTGGTTGAGCCGGGGGTTGCAAGAGAAGCCG TTGTCCATCGCGTTGCGCGAGATCCACGCCGATCTGCTCGAGCACACCGAGGGCGAGTAG	
Τ7	Used in <i>in vitro</i> transcription assay with T7 RNAP	TTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAAATAATTTTGTTTAAC TTTAGAAGGAGATATACATATGCACCATCATCATCATCATCTCTGGTCTGGTGCCACGCGGTTCTG GTATGAAAGAAACCGCTGCTGCTAAATTCGAACGCCAGCACATGGACAGCCCAGATCTGGGTACCGA CGACGACGACAAGGCCATGGCTGATATCGGATCCGAATTCGAGCTCCGTCGACAAGCTTGCGGCCG CACTCGAGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTT GGCTGCTGCCACCGCTGAGCAATAACTAGC	
T7A1	Used in <i>in vitro</i> transcription assay with EcRNAPholo	CGGAATTCGGATCCAGATCCCGAAAATTTATCAAAAAGAGTATTGTAAAGTCTAACCTATAGGATACTTA CAGCC A TCGAGAGGGACACGGGCGAAGCTTGGATCGAATCGAAGAAGCTACTCGTAATTTCACGGGTT ATAAACCTGTGAAAAAGG	

Name of the vector	Source	Resistance Marker
pAcYc Duet	Novagen, USA	Chloramphenicol
pET Duet	Novagen, USA	Ampicillin
pET 28a(+)	Novagen, USA	Kanamycin
pUC19	New England Biolabs, UK	Ampicillin
pBluescript II SK(+)	Agilent technologies, USA	Ampicillin
pLAM12	Addgene, USA	Kanamycin
pFPV mcherry	Addgene, USA	Ampicillin

Supplementary Table 3: List of vectors used in this study

Supplementary Table 4: List of plasmids

pETDuet-rpoB-rpoC	Banerjee et al.
pAcYc- <i>rpoA-sigE</i>	This study
pET28a-rv1222	This study
pAcYc-rv1222	This study
pAcYc-rv1222∆C	This study
pFPV-mcherryUV5	This study
pLAM12-Rv1222	This study
pUC19- lacCONS	This study
pET29a- <i>sigA</i>	Banerjee et al.
pET30a- <i>sigE</i>	Rodrigue et al.
pET16b- <i>rpoA</i>	Rodrigue et al.
pBluescriptSK- <i>Bpr</i>	This study

*.:



Supplementary Figure 1: Inhibition of transcription by Rv1222 purified from soluble fraction: Open complex was formed with 100nM Ec RNAP holo and 50nM *lacCONS* DNA. Rv1222 was added after open complex formation. Transcripts were produced using P³² labelled NTPs.



Supplementary Figure 2A: Full gel of SigE transcription assay with Rv1222.

Supplementary Figure 2B: Nuclease assay: P³² labelled transcripts (81nt) were formed using *in vitro* transcription assay with 100nM Ec RNAP and 50nM *T7A1* template DNA. The samples were

treated with increasing concentrations of Rv1222 for 5mins at 37 ℃ and loaded in denaturing PAGE and scanned by autoradiography.



Supplementary Figure 3: *In vitro* transcription assay with 100nM Ec RNAP core, Rv1222 and 28ng Kool NC-45 template (14ng/μl) (Epicenter, USA). Lane 1: Control, no DNA. Lane 2-5: increasing concentrations of Rv1222. Rv1222 was incubated with the core enzyme before the open complex formation. RNA transcript produced were monitored by fluorescence with Ex at 490nM; Em at 530nM.



Supplementary Figure 4: Binding of TMR labelled Rv1222 (20nM) to Mtb σ^{E} and Mtb σ^{A} :Fluorescence anisotropy assay.



Supplementary Figure 5: Binding of TMR labelled Rv1222 (20nM) to promoter-less DNA fragment. Sequence of DNA was shown in Supplementary table 1.



Supplementary Figure 6: Effect of salt concentration on Rv1222 activity.

A. Binding assay with RNAP: 20nM TMR labelled Rv1222 was titrated with Mtb RNAPcore in a transcription buffer containing 200mM KCI. Fluorescence anisotropy of the labelled protein were monitored at Ex 530 nm and Em 580 nm.

B. Binding assay with DNA: Same as A except Rv1222 was titrated with promoter DNA(*lacCONS* DNA).

C. *In vitro* transcription assay: Open complex was formed with 100nM Ec RNAP holo and 50nM *lacCONS* DNA in above transcription buffer and incubated with Rv1222 before transcription initiation.



Supplementary Figure 7: A. *In vitro* transcription assay with Fe-BABE labelled Rv1222 derivatives. 100nM Mtb RNAP(σ^{E})holo and 50nM *Bpr* promoter DNA was used to form the open complex. Rv1222 derivatives was added and incubated for 30mins at 37 °C followed by addition of NTP (125µM ATP, GTP, CTP, and 20 µM α^{32P} -CTP (0.4 µCi)). After 5 min, the reactions were terminated by addition of 2.5 µl of FLB dye.

- A. Result with Rv1222 A23C derivative.
- B. Result with Rv1222 G133C derivative.



Supplementary Figure 8: DNA-Protein footprinting with Fe-BABE labelled Rv1222.Lane 1: No Rv1222; Lane 2: labelled Rv1222 at residue A23C (N-ter); Lane 3: labelled Rv1222 at residue G133C (C-ter). Arrows indicate the site of cleavage.



Supplementary Figure 9: Rv1222 inhibits transcription elongation. Stalled elongation complex (EC +23) were formed by *in vitro* transcription assay with 100nM Ec RNAP holo and 50nM *T7A1* promoter that had the first template-strand adenine residue at position +23, with 5 μ M of ATP, GTP and 2.5 μ M of α^{32P} -CTP (0.2 μ Ci). After the formation of EC, the stalled complexes were incubated with increasing concentrations of Rv1222 for 10min at 37 °C and chased with 5 μ M UTP for 5mins.